Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

The health clinic where Alice Okwirry collects her HIV medication in Kenya's capital Nairobi has been rationing supplies of ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Merck (NYSE:MRK) said that data from a pair of late-stage trials showed that an oral, two-drug regimen of ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

A new formulation of Gilead's HIV prevention drug, lenacapavir, has shown promise in providing yearlong protection with just one injection. The study, published in The Lancet, evaluated the ...

Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...

A bill filed in Springfield would allow doctors to prescribe some HIV medication without needing prior authorization.

The commodities, which were flagged off by Health Cabinet Secretary Deborah Barasa on Friday, March 14, include ARV drugs ...